WO2002069944A3 - Nouvelles compositions medicamenteuses a base d'anticholinergiques et d'antagonistes de recepteurs nk1 - Google Patents

Nouvelles compositions medicamenteuses a base d'anticholinergiques et d'antagonistes de recepteurs nk1 Download PDF

Info

Publication number
WO2002069944A3
WO2002069944A3 PCT/EP2002/001987 EP0201987W WO02069944A3 WO 2002069944 A3 WO2002069944 A3 WO 2002069944A3 EP 0201987 W EP0201987 W EP 0201987W WO 02069944 A3 WO02069944 A3 WO 02069944A3
Authority
WO
WIPO (PCT)
Prior art keywords
anticholinergics
receptor antagonists
compositions based
medicament compositions
novel medicament
Prior art date
Application number
PCT/EP2002/001987
Other languages
German (de)
English (en)
Other versions
WO2002069944A2 (fr
Inventor
Christopher John Montagu Meade
Michel Pairet
Michael Paul Pieper
Original Assignee
Boehringer Ingelheim Pharma
Christopher John Montagu Meade
Michel Pairet
Michael Paul Pieper
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA03008051A priority Critical patent/MXPA03008051A/es
Application filed by Boehringer Ingelheim Pharma, Christopher John Montagu Meade, Michel Pairet, Michael Paul Pieper filed Critical Boehringer Ingelheim Pharma
Priority to AU2002251010A priority patent/AU2002251010A1/en
Priority to CA002439915A priority patent/CA2439915A1/fr
Priority to JP2002569121A priority patent/JP2004519484A/ja
Priority to EP02719915A priority patent/EP1370293A2/fr
Publication of WO2002069944A2 publication Critical patent/WO2002069944A2/fr
Publication of WO2002069944A3 publication Critical patent/WO2002069944A3/fr
Priority to AU2006202723A priority patent/AU2006202723B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La présente invention concerne de nouvelles compositions médicamenteuses à base d'anticholinergiques et d'antagonistes de récepteurs NK1, leur procédé de production et leur utilisation dans le cadre du traitement de maladies des voies respiratoires.
PCT/EP2002/001987 2001-02-23 2002-02-26 Nouvelles compositions medicamenteuses a base d'anticholinergiques et d'antagonistes de recepteurs nk1 WO2002069944A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MXPA03008051A MXPA03008051A (es) 2001-03-08 2002-02-22 Nuevas composiciones farmaceuticas a base de anticolinergicos y/o antagonistas del receptor nk1.
AU2002251010A AU2002251010A1 (en) 2001-03-08 2002-02-26 Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists
CA002439915A CA2439915A1 (fr) 2001-03-08 2002-02-26 Nouvelles compositions pharmaceutiques a base d'anticholinergiques et d'antagonistes de recepteurs nk1
JP2002569121A JP2004519484A (ja) 2001-03-08 2002-02-26 抗コリン作動薬およびｎｋ１−レセプタアンタゴニストに基づく新規医薬組成物
EP02719915A EP1370293A2 (fr) 2001-03-08 2002-02-26 Nouvelles compositions medicamenteuses a base d'anticholinergiques et d'antagonistes de recepteurs nk1
AU2006202723A AU2006202723B2 (en) 2001-02-23 2006-06-26 Novel genes encoding novel proteolytic enzymes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10111058A DE10111058A1 (de) 2001-03-08 2001-03-08 Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und NK¶1¶-Rezeptor-Antagonisten
DE10111058.8 2001-03-08

Publications (2)

Publication Number Publication Date
WO2002069944A2 WO2002069944A2 (fr) 2002-09-12
WO2002069944A3 true WO2002069944A3 (fr) 2003-10-02

Family

ID=7676673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/001987 WO2002069944A2 (fr) 2001-02-23 2002-02-26 Nouvelles compositions medicamenteuses a base d'anticholinergiques et d'antagonistes de recepteurs nk1

Country Status (7)

Country Link
EP (1) EP1370293A2 (fr)
JP (1) JP2004519484A (fr)
AU (1) AU2002251010A1 (fr)
CA (1) CA2439915A1 (fr)
DE (1) DE10111058A1 (fr)
MX (1) MXPA03008051A (fr)
WO (1) WO2002069944A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
DE10214264A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen eines Anhydrats
DE10230750A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholonergika und NK1-Rezeptor-Antagonisten
WO2005004875A1 (fr) * 2003-07-14 2005-01-20 Sankyo Company, Limited Composition medicinale a administration pulmonaire
JP2006160639A (ja) * 2004-12-06 2006-06-22 Sankyo Co Ltd ニューロキニン受容体拮抗剤と抗コリン剤の併用
ITRM20120331A1 (it) * 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.
WO2015111627A1 (fr) * 2014-01-21 2015-07-30 味の素株式会社 Acide aminé de sucre et application associée

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0581167A1 (fr) * 1992-07-27 1994-02-02 Kyorin Pharmaceutical Co., Ltd. Dérivés de arylglycinamide, leur procédé de préparation et leur usage pour le traitement de la dysurie
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
WO1997032865A1 (fr) * 1996-03-06 1997-09-12 Boehringer Ingelheim Pharma Kg Nouveaux derives d'arylglycinamide, leur procede de fabrication et compositions pharmaceutiques contenant ces composes
WO1999064010A1 (fr) * 1998-06-11 1999-12-16 Merck Sharp & Dohme Limited Utilisation d'un antagoniste du recepteur nk-1 dans le traitement des troubles psychiatriques
US6124319A (en) * 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0581167A1 (fr) * 1992-07-27 1994-02-02 Kyorin Pharmaceutical Co., Ltd. Dérivés de arylglycinamide, leur procédé de préparation et leur usage pour le traitement de la dysurie
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
WO1997032865A1 (fr) * 1996-03-06 1997-09-12 Boehringer Ingelheim Pharma Kg Nouveaux derives d'arylglycinamide, leur procede de fabrication et compositions pharmaceutiques contenant ces composes
US6124319A (en) * 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
WO1999064010A1 (fr) * 1998-06-11 1999-12-16 Merck Sharp & Dohme Limited Utilisation d'un antagoniste du recepteur nk-1 dans le traitement des troubles psychiatriques

Also Published As

Publication number Publication date
MXPA03008051A (es) 2003-12-04
EP1370293A2 (fr) 2003-12-17
AU2002251010A1 (en) 2002-09-19
WO2002069944A2 (fr) 2002-09-12
DE10111058A1 (de) 2002-09-12
JP2004519484A (ja) 2004-07-02
CA2439915A1 (fr) 2002-09-12

Similar Documents

Publication Publication Date Title
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
WO2003084539A3 (fr) Nouvelles compositions pharmaceutiques a base d'anticholinergiques et d'inhibiteurs de la kinase p38
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
WO2002069945A3 (fr) Nouvelles preparations de medicaments a base d'anticholinergiques et d'inhibiteurs pde-iv
WO2002047668A3 (fr) Nouvelles compositions medicamenteuses a base d'anticholinergiques et de ciclesonide
TW200621765A (en) Substituted phenylaminothiazoles and their use
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
WO2004071529A3 (fr) Utilisations d'anticorps contre le recepteur de facteur de croissance insulinoide i
IL164108A (en) Quinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of medicaments for the treatment of cns and other disorders
WO2003096990A3 (fr) Cages proteiques pour l'administration d'agents therapeutiques et d'imagerie medicale
AU2003289888A1 (en) Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
CA2436540A1 (fr) Composition pharmaceutique a base d'anticholinergiques et de corticosteroides
WO2003087049A3 (fr) Combinaisons de produits pharmaceutiques contenant des composes heterocycliques et un nouvel anticholinergique
WO2002088100A3 (fr) 3-piperidinopropiophenones dopees et produits pharmaceutiques contenant ces composes
WO2006015970A3 (fr) Medicaments pour la prevention ou le traitement de la pneumonie alveolaire comprenant un anticholinergique
EP1262197A3 (fr) Combinaison thérapeutique pour traiter les troubles du sommeil, y compris l'apnée du sommeil
WO2002069944A3 (fr) Nouvelles compositions medicamenteuses a base d'anticholinergiques et d'antagonistes de recepteurs nk1
WO2005094798A3 (fr) Compositions pharmaceutiques a base d'anticholinergiques et d'antagonistes du recepteur ccr2
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
WO2005123113A3 (fr) Compositions d'interferons et leurs methodes d'utilisation
WO2002074034A3 (fr) Nouvelles compositions medicamenteuses a base d'anticholinergiques et d'antagonistes de l'endotheline
AU2003245989A1 (en) Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
WO2005063757A3 (fr) Nouvelles formes cristallines de temozolomide
WO2000076500A8 (fr) Compound for use as a medicament for treatment of disorders involving bronchocontraction
WO2004105759A3 (fr) Nouvelles combinaisons medicamenteuses a action prolongee utilisees pour traiter des maladies des voies respiratoires

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002719915

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2439915

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/008051

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002569121

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002719915

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642